Monday, September 30, 2013

Hewlett-Packard Lowers Notebook Estimates for 2014 (HPQ)

The Palo Alto-based computer manufacturer Hewlett-Packard (HPQ) announced on Monday that it expects to ship significantly fewer notebooks in the coming year.

According to an internal forecast, the company is expected to ship 21 million laptop units in 2014, which would mark a serious deterioration from 2012′s sales figure of 32 million units. Looking out even further, it was reported that HP’s 2015 sales figure could be as low as 19 million units; as far as the current year goes, most are predicting sales of fewer than 30 million units. The undeniable shift into the mobile space has resonated well for tablets, while taking a big bite out of HP’s “bread and butter” notebook division.

Hewlett-Packard shares traded sideways on Monday, gaining 0.38% on the day. The stock is up nearly 57% YTD.

Sunday, September 29, 2013

Chevron Will Settle $17.5 Billion Oil Spill Claim for Pennies

Following a November 2011 leak of about 3,600 barrels of oil from a rig offshore of Brazil, Chevron Corp. (NYSE: CVX) and driller Transocean Ltd. (NYSE: RIG) were slapped with a penalty of $17.5 billion by the government's public prosecutor's office. That payment reportedly has been reduced to less than $42 million as the company and the government have agreed on a settlement.

According to a report from the Financial Times, Chevron has agreed to incorporate a number of new procedures to prevent this kind of accident from happening again. In a statement from the public prosecutor's office a spokesman said:

With the signature of the [accord], which will commit Chevron to take unprecedented action to prevent new incidents and compensate for the spills that occurred in the Frade field — the two suits may be resolved.

The oil from the relatively small spill never reached the Brazilian coast, but that did not soothe official reaction to the accident. The massive original penalty was only slightly less than the $20 billion fund the U.S. government forced BP PLC (NYSE: BP) to establish after the Macondo well explosion killed 11 workers and dumped 5 million barrels of oil into the Gulf of Mexico.

In addition to the fine, Chevron and its partners will cover the cost of implementing the new preventive measures on their own operations.

Chevron continues to battle an Ecuadoran award of around $18 billion for environmental damage in that country caused by Texaco before its 2001 merger with Chevron.

Saturday, September 28, 2013

Is CBS a Buy At Current Prices?

With shares of CBS (NYSE:CBS) trading around $53, is CBS an OUTPERFORM, WAIT AND SEE, or STAY AWAY? Let's analyze the stock with the relevant sections of our CHEAT SHEET investing framework:

T = Trends for a Stock’s Movement

CBS operates as a mass media company in the United States and abroad. The company operates in the entertainment, cable networks, publishing, local broadcasting, and outdoor segments. Consumers seek entertainment of various forms and through an array of platforms at an increasing rate, and through its segments, CBS is able to fulfill consumer needs as it continues to release content that excites the masses. Consumers around the world always seek varied forms of entertainment, and CBS is dedicated to delivering that media, which can only lead to growth and rising profits well into the future.

CBS and Time Warner Cable's (NYSE:TWC) battle over retransmission fees is now settled, to the advantage of CBS. Time Warner Cable is being forced to pay a significant increase in retransmission fees, although the figure is still below $2 per subscriber per month. The blackout of CBS programming from Time Warner Cable is now ending, just in time for the start of the NFL season.

T = Technicals on the Stock Chart Are Strong

CBS stock has been flying higher over the last several years. The stock is now trading near all-time high prices and looks poised to continue. Analyzing the price trend and its strength can be done using key simple moving averages. What are the key moving averages? The 50-day (pink), 100-day (blue), and 200-day (yellow) simple moving averages. As seen in the daily price chart below, CBS is trading above its rising key averages which signal neutral to bullish price action in the near-term.

CBS

(Source: Thinkorswim)

Taking a look at the implied volatility (red) and implied volatility skew levels of CBS options may help determine if investors are bullish, neutral, or bearish.

Implied Volatility (IV)

30-Day IV Percentile

90-Day IV Percentile

CBS Options

28.36%

60%

57%

What does this mean? This means that investors or traders are buying a significant amount of call and put options contracts as compared to the last 30 and 90 trading days.

Put IV Skew

Call IV Skew

September Options

Flat

Average

October Options

Flat

Average

As of today, there is an average demand from call buyers or sellers and low demand by put buyers or high demand by put sellers, all neutral to bullish over the next two months. To summarize, investors are buying a significant amount of call and put option contracts and are leaning neutral to bullish over the next two months.

On the next page, let’s take a look at the earnings and revenue growth rates and the conclusion.

E = Earnings Are Increasing Quarter-Over-Quarter

Rising stock prices are often strongly correlated with rising earnings and revenue growth rates. Also, the last four quarterly earnings announcement reactions help gauge investor sentiment on CBS’s stock. What do the last four quarterly earnings and revenue growth (Y-O-Y) figures for CBS look like and more importantly, how did the markets like these numbers?

2013 Q2

2013 Q1

2012 Q4

2012 Q3

Earnings Growth (Y-O-Y)

16.92%

27.78%

9.32%

20.00%

Revenue Growth (Y-O-Y)

6.42%

6.43%

2.99%

1.58%

Earnings Reaction

3.86%

2.04%

3.95%

1.05%

CBS has seen rising earnings and revenue figures over the last four quarters. From these numbers, the markets have been upbeat about CBS’s recent earnings announcements.

P = Excellent Relative Performance Versus Peers and Sector

How has CBS stock done relative to its peers Comcast (NASDAQ:CMCSA), Twenty-First Century Fox (NASDAQ:FOXA), Disney (NYSE:DIS), and sector?

CBS

Comcast

Twenty-First Century Fox

Disney

Sector

Year-to-Date Return

41.84%

14.13%

45.47%

23.88%

29.58%

CBS has been a relative performance leader, year-to-date.

Conclusion

CBS is one of the largest nationwide providers of entertainment and mass media services. The company's dispute with Time Warner Cable is now settled, to the benefit of CBS. The stock has been rising higher over the last few years and is now trading near all-time high prices. Over the last four quarters, earnings and revenues have been increasing which have resulted in upbeat investors. Relative to its peers and sector, CBS has been a year-to-date performance leader. Look for CBS to OUTPERFORM.

Thursday, September 26, 2013

Top Canadian Stocks To Invest In Right Now

Modules of Canadian Solar Inc. (CSIQ) have been selected by Argand Energy Solutions for their solar project located in Louisburg, NC. In collaboration with Horne Brothers Construction, Inc., Argand Energy Solutions began construction of the 2.3 megawatt (MW) project in Jun 2013. System grid connection is scheduled for Aug 2013.

The utility solar power system will utilize approximately 7,700 of Canadian Solar's CS6X-300P photovoltaic (PV) modules. CS6X-300P PV modules are polycrystalline silicon modules that carry a warranty period of 10 years on materials and workmanship and a 25-year warranty on linear power output performance.

With power tolerances in the range of 0% to 2.0%, these modules have maximum system voltage of 1000V. With respect to quality control inspections and testing, these modules have received key international certifications. Post completion, these highly efficient modules will allow the project to power approximately 460 homes.

Top Canadian Stocks To Invest In Right Now: Innovaro Inc(INV)

Innovaro, Inc. provides a comprehensive portfolio of end-to-end innovation solutions primarily in the United States and the United Kingdom. It helps clients develop compelling strategies to drive and catalyze growth, source externally developed technologies, create added value from their intellectual property, and gain foresight into marketplace and technology developments that affect their business. The company operates in two segments, Strategic Services and Technology Services. The Strategic Services segment offers strategic innovation consulting; business model and product development consulting; identify and develop new segments and markets; and create and act on game-changing strategies. The Technology Services segment provides futures scenario development and planning; custom and syndicated research; online information services; IP consulting; IP and market landscape analysis; technology search; In- and out-licensing; online marketplaces; and partner search and prof iling services. Its clients include consumer goods, consumer packaged goods, retail, medical, telecommunications, chemicals, media, financial services, energy, utilities, and government agencies. The company was formerly known as UTEK Corporation and changed its name to Innovaro, Inc. in July 2010. Innovaro, Inc. is based in Tampa, Florida.

Top Canadian Stocks To Invest In Right Now: Alexandria Real Estate Equities Inc. (ARE)

Alexandria Real Estate Equities, Inc., a real estate investment trust (REIT), engages in the ownership, operation, management, development, acquisition, and redevelopment of properties for the life sciences industry. Its properties consist of buildings containing scientific research and development laboratories, and other improvements. The company offers its properties for lease primarily to universities and independent not-for-profit institutions; and pharmaceutical, biotechnology, medical device, life science product, service, biodefense, and translational research entities, as well as governmental agencies. As of December 31, 2006, it had 159 properties, including 156 properties located in 9 states in the United States and 3 properties located in Canada. As a REIT, the company is not subject to federal income tax to the extent that it distributes 100% of its taxable income to its stockholders. The company was founded in 1993 and is based in Pasadena, California.

Advisors' Opinion:
  • [By Markus Aarnio]

    Owens Realty Mortgage's competitors include American Assets Trust (AAT), Alexandria Real Estate Equities (ARE) and Boston Properties (BXP). American Assets Trust has seen five insider buy transactions and four insider sell transactions this year. American Assets Trust has a dividend yield of 2.78%. Alexandria Real Estate Equities has seen 14 insider sell transactions this year. Alexandria Real Estate Equities has a dividend yield of 4.10%. Boston Properties has seen one insider buy transaction and four insider sell transactions this year. Boston Properties has a dividend yield of 2.43%.

  • [By Shauna O'Brien]

    Real estate investment trust Alexandria Real Estate Equities Inc (ARE) announced on Tuesday that its board has approved a 4.6% increase to its quarterly dividend.

    The firm has raised its dividend from 65 cents to 68 cents per share, or $2.72 annually. The dividend will be paid on October 15 to shareholders of record on September 30. The stock will go ex-dividend on September 26.

    Alexandria Real Estate Equities shares were mostly flat during pre-market trading Tuesday. The stock is down 9% YTD.

Top Safest Stocks To Invest In Right Now: Ormat Technologies Inc.(ORA)

Ormat Technologies, Inc., together with its subsidiaries, engages in the geothermal and recovered energy power business in the United States and internationally. The company operates in two segments, Electricity and Product. The Electricity segment develops, builds, owns, and operates geothermal and recovered energy-based power plants; and sells the electricity. The Product segment designs, manufactures, and sells power units for geothermal and recovered energy-based electricity generation; fossil fuel powered turbo-generators; and heavy duty direct-current generators. It also provides services relating to the engineering, procurement, construction, operation, and maintenance of geothermal and recovered energy power plants. This segment serves contractors and geothermal power plant owners and operators; and interstate natural gas pipeline owners and operators, gas processing plant owners and operators, cement plant owners and operators, and companies in other energy-intens ive industrial processes. The company was founded in 1965 and is based in Reno, Nevada. Ormat Technologies, Inc. is a subsidiary of Ormat Industries Ltd.

Advisors' Opinion:
  • [By Amy Thomson]

    AT&T has examined takeover candidates including Vodafone�� assets, U.K. mobile carrier EE -- a venture of Deutsche Telekom AG (DTE) and Orange SA (ORA) -- and parts of Spain�� Telefonica SA (TEF), people familiar with the company�� plans said in June. AT&T is attracted to Europe because of its relatively recent introduction of faster, fourth-generation networks, which have been available for years in the U.S.

Top Canadian Stocks To Invest In Right Now: Windstream Corporation(WIN)

Windstream Corporation provides communications and technology solutions in the United States. The company offers various solutions, including IP-based voice and data services, multiprotocol label switching (MPLS) networking, data center and managed services, hosting services, and communications systems to businesses and government agencies. It also provides high-speed Internet, voice, and digital television services to residential customers primarily located in rural areas. The company?s data services include data center and managed hosting, MPLS networking, and dedicated access, as well as high-speed Internet to business customers; integrated solutions consist of multiple voice and data services delivered over an IP connection; voice services comprise local and long distance, call waiting, caller identification, and voicemail; and special access services include point-to-point switching arrangements for voice and data traffic. In addition, it provides wholesale services, which primarily include voice and data services on a wholesale basis to other carriers; usage sensitive services to long distance companies; and other local exchange carriers for access to the network in connection with the completion of long-distance calls, as well as reciprocal compensation received from wireless and other local connecting carriers for the use of its facilities. As of June 30, 2011, the company served approximately 3.3 million access lines, 1.3 million high-speed Internet customers, and operated approximately 60,000 fiber route miles. Windstream Corporation is based in Little Rock, Arkansas.

Top Canadian Stocks To Invest In Right Now: UniSource Energy Corporation(UNS)

UniSource Energy Corporation engages in the electric generation and energy delivery businesses. The company?s TEP segment generates, transmits, and distributes electricity to approximately 403,000 retail electric customers, including residential, commercial, industrial, and public sector customers in southeastern Arizona. It also sells electricity to other utilities and power marketing entities. As of December 31, 2010, this segment owned or leased 2,245 MW of net generating capacity, as well as owned or participated in electric transmission and distribution system consisting of 512 circuit-miles of 500-kV lines; 1,087 circuit-miles of 345-kV lines; 379 circuit-miles of 138-kV lines; 478 circuit-miles of 46-kV lines; and 2,621 circuit-miles of lower voltage primary lines. TEP segment generates electricity from coal, gas, oil, and solar sources. The company?s UNS Gas segment distributes gas to approximately 146,500 retail customers in Mohave, Yavapai, Coconino, and Navajo c ounties in northern Arizona, as well as Santa Cruz County in southeastern Arizona. As of December 31, 2010, this segment?s transmission and distribution system consisted of approximately 30 miles of steel transmission mains, 4,211 miles of steel and plastic distribution piping, and 136,439 customer service lines. The company?s UNS Electric segment transmits and distributes electricity to approximately 91,000 retail customers consisting of residential, commercial, and industrial customers in Mohave and Santa Cruz counties. As of December 31, 2010, UNS Electric?s transmission and distribution system consisted of approximately 56 circuit-miles of 115-kV transmission lines, 271 circuit-miles of 69-kV transmission lines, and 3,599 circuit-miles of underground and overhead distribution lines. This segment also owns the 65 MW Valencia plant, as well as 39 substations having an installed capacity of 1,788,050 kilovolt amperes. The company was founded in 1902 and is based in Tucson, Arizona.

Top Canadian Stocks To Invest In Right Now: Talisman Energy Inc.(TLM)

Talisman Energy Inc., an upstream oil and gas company, engages in the exploration, development, production, transportation, and marketing of crude oil, natural gas, and natural gas liquids. It primarily operates in North America, the North Sea, and southeast Asia. The company was founded in 1925 and is headquartered in Calgary, Canada.

Advisors' Opinion:
  • [By Value Digger]

    Manitok's competitive advantage is its management team, who knows well where the shallow opportunities exist, from years of bypassing many conventional reservoirs and drilling deeper targets for Talisman Energy (TLM).

Top Canadian Stocks To Invest In Right Now: Chipotle Mexican Grill Inc.(CMG)

Chipotle Mexican Grill, Inc. develops and operates fast-casual, fresh Mexican food restaurants in the United States, Canada, and England. Its restaurants primarily offer burritos, tacos, burrito bowls, and salads. As of December 31, 2011, it operated 1,230 restaurants, which includes 1 ShopHouse Southeast Asian Kitchen. Chipotle Mexican Grill, Inc. was founded in 1993 and is based in Denver, Colorado.

Advisors' Opinion:
  • [By Dividend Growth Investor]

    [ Enlarge Image ]
    The company�� international operations have fueled the strong growth in McDonald�� earnings over the past twenty years. Despite the fact that a little over half of the company�� profits are derived internationally, this segment could continue to deliver solid performance in the future. Another factor fueling the company�� growth and maintenance of its edge against competitors and other threats has been its ability to innovate in its menu and reinvent itself in order to win. Some examples of that include the addition of salads to its menu a few years ago, as well as the introductions of premium drinks for customers. Other examples include extending store hours as well as focusing on the core brands through disposition of Chipotle Mexican Grill (CMG). The company has also been able to focus on streamlining operations and focusing on same-store sales, rather than mindlessly expanding at all costs. However, it still plans on expanding store count, while also reimaging existing locations, in order to improve the customer experience.

  • [By Ben Levisohn]

    Their favorites: Chipotle Mexican Grill (CMG) and Starbucks (SBUX). They explain why:

    For Starbucks, we anticipate continued potential for earnings upside on remarkably healthy and consistent same-store sales trends (which we believe have continued into the September quarter), with its June quarter comp of 9% leading the entire restaurant industry, despite more than 19,000 global locations. For Chipotle, we remain heartened by strong midsingle-digit same-store traffic gains, with a likely price increase in the first half of 2014 poised to provide upward momentum to estimates, particularly as Chipotle has already absorbed significant commodity inflation that has increased its cost of sales to 33%-plus.

  • [By AlphaStreetResearch]

    Buffalo Wild Wings (BWLD) has been a hot growth stock, but this company has plenty of room to run higher as the firm continues to execute its domestic and international growth strategy. This is a company with huge potential in Restaurant and Services sector as the company's customer base continues to grow and remain loyal. Below is our introduction into its business model, it's strengths, and the buying opportunity that currently exists for Buffalo Wild Wings. Wall Street has not yet realized the full potential of this company as it continues to be seen as a seasonality play in this space. The company continues to prove this stigma wrong. The company has a market cap of $2.06 Billion and reports the next quarter on October 21, 2013. With this in mind, we value Buffalo Wild Wings at $123.00 by year-end of 2013 and $138.00 by May 1, 2014, an increase of 28% from current levels. We strongly feel that this company has the potential to see major upside over the next year and we could see the stock continue to run like Chipotle (CMG) or Panera (PNRA) in recent history. Dining and entertainment demand is growing and Buffalo Wild Wings continues to take market share, as the company has some of the best customer retention rates and average ticket sales in the sector. We will later highlight:

Top Canadian Stocks To Invest In Right Now: Thor Industries Inc.(THO)

Thor Industries, Inc., together with its subsidiaries, manufactures and sells a range of recreation vehicles and small and mid-size buses, as well as related parts and accessories in the United States and Canada. The company offers a range of travel trailers and motorhomes under the trade name of Airstream, which include Airstream Safari, International, Flying Cloud, and Bambi travel trailers, as well as Interstate Class B motorhomes. It also manufactures and sells conventional travel trailers and fifth wheels under the trade names of Dutchmen, Four Winds, Aero, Grand Junction, Colorado, Cruiser, Seville, Zinger, and Sunset Trail; travel trailers and fifth wheels under trade names of Montana, Springdale, Hornet, Sprinter, Outback, Laredo, Everest, Mountaineer, Challenger, Cougar, Komfort, and Trailblazer; and gasoline and diesel Class C, Class A, and Class B motorhomes under the trade names of Four Winds, Hurricane, Windsport, Mandalay, Dutchmen, Chateau, Serrano, Ventura, and Fun Mover. In addition, it manufactures and sells gasoline and diesel Class A motor homes under the trade names of Daybreak, Challenger, Astoria, Tuscany, Outlaw, and Avanti; travel trailers, fifth wheels, truck campers, and park models under the trade name of General Coach; and park models under the trade names of Tranquility, Westchester, and Breckenridge. Further, the company manufactures small and mid-size transit and commercial buses under the trade names of Aerolite, AeroElite, Aerotech, Escort, MST, Transmark, EZ Rider, Axess, Challenger, Defender, Crusader, American Cruiser, Classic Coach, EZ Trans, GC II, and Pacer. It markets its vehicles through independent dealers to municipalities and private purchasers, such as rental car companies and hotels. The company has a joint venture agreement with Cruise America, Inc. to provide short-term rentals of motorized recreation vehicles to the public. Thor Industries was founded in 1980 and is based in Jackson Center, Oh io.

Advisors' Opinion:
  • [By Roberto Pedone]

    My first earnings short-squeeze trade idea is recreational vehicle maker Thor Industries (THO), which is set to release numbers on Thursday after the market close. Wall Street analysts, on average, expect Thor Industries to report revenue of $964.54 million on earnings of 95 cents per share.

    The current short interest as a percentage of the float Thor Industries is notable at 6.7%. That means that out of the 50.23 million shares in the tradable float, 3.01 million shares are sold short by the bears. If the bulls get the earnings news they're looking for, then shares of THO could easily rip sharply higher post-earnings.

    From a technical perspective, THO is currently trending above both its 50-day and 200-day moving averages, which is bullish. This stock has been uptrending strong for the last six months, with shares moving higher from its low of $34.38 to its recent high of $55.93 a share. During that uptrend, shares of THO have been making mostly higher lows and higher highs, which is bullish technical price action. That move has now pushed shares of THO within range of triggering a big breakout trade post earnings.

    If you're bullish on THO, then I would wait until after its report and look for long-biased trades if this stock manages to break out above some near-term overhead resistance levels at $55.29 to its 52-week high at $55.93 a share with high volume. Look for volume on that move that hits near or above its three-month average action of 397,012 shares. If that breakout hits, then THO will set up to enter new 52-week-high territory, which is bullish technical price action. Some possible upside targets off that move are $65 to $70 a share.

    I would simply avoid THO or look for short-biased trades if after earnings it fails to trigger that breakout, and then drops back below some key near-term support levels at its 50-day moving average of $53.11 to $52.52 a share with high volume. If we get that move, then THO will set up to

Wednesday, September 25, 2013

After the Sourcefire (FIRE) Deal: Who Could be Next in the IT Security Space? PANW & FTNT

On Tuesday, small cap security software stock Sourcefire, Inc (NASDAQ: FIRE) surged after Cisco Systems, Inc (NASDAQ: CSCO) announced it would acquire the company in a deal worth $2.7 billion, pretty much leaving mid cap stocks Palo Alto Networks Inc (NYSE: PANW) and Fortinet Inc (NASDAQ: FTNT) left for investors or acquirers in the IT or cybersecurity space. Sourcefire itself is a top maker of next-generation intrusion prevention software, firewalls and malware protection for companies and government agencies. The deal puts Cisco even deeper into the key network security field with observers saying it could foreshadow other acquisitions in the space by other large cap IT players. Moreover, Christopher Young, senior vice president of Cisco's security group, was quoted in Investors Business Daily as saying:

"We have adversaries out there that are constantly trying to figure out ways to defeat us, so as that landscape changes we will respond — if we have to respond organically, if we have to respond inorganically."

What You Need to Know About Palo Alto Networks Fortinet

With the above in mind, here is what you need to know about mid caps Palo Alto Networks and Fortinet:

Palo Alto Networks. Offering a network security platform that allows enterprises, service providers and government entities to secure their networks, Palo Alto Networks pioneered the next generation of network security and has more than 12,500 enterprise, government and service provider customers worldwide - including many Fortune 500 companies. Palo Alto Networks' CFO recently said the enterprise network security segment is "robust." However, Palo Alto Networks is starting to hit bumps in its growth story that was not helped with its latest earnings report where investors were "expecting a home run quarter while the company scored a single or a double" in the words of one analyst. Specifically, the company reported a loss of $7.3 million, or 10 cents per share, compared with a profit of $0.8 million a year earlier. On Tuesday, Palo Alto Networks fell 2.04% to $48.54 (PANW has a 52 week trading range of $39.08 to $72.61 a share) for a market cap of $3.45 billion plus PANW is down 7.8% since the start of the year and down 8.6% over the past year (Note: The company went public last July). It should also be noted that more than 2,800 August 55 calls recently traded, but the company also has a rather high forward P/E of 121.35 with the next earnings report scheduled for September 9th.

Fortinet. A worldwide provider of network security appliances and a market leader in unified threat management (UTM), Fortinet's customers include enterprises, service providers and government entities worldwide - including the majority of the 2011 Fortune Global 100. The last time Fortinet reported earnings, the numbers were in line with its pre-announcement early in April, but the guidance for the current period fell short of what Wall Street had expected due to a few large service provider deals not closing and weakness in particular geographies. Nevertheless, many analysts remained upbeat but for what its worth, CNBC's Mad Money host recently said: "I'm a seller. I feel bad for anyone holding this stock." On Tuesday, Fortinet rose 4.84% to $21.43 (FTNT has a 52 week trading range of $16.47 to $28.23 a share) for a market cap of $3.47 billion plus FTNT is up 2.4% since the start of the year, down 8.7% over the past year and up 153% since November 2009. Fortinet will next report earnings on July 30th and it has a trailing P/E of 56.39 along with a forward P/E of 35.72.

10 Best Small Cap Stocks To Own For 2014

Share Performance: Sourcefire, Inc vs. Palo Alto Networks and Fortinet

Here is a quick look at the short term and longer term performance of Sourcefire verses Palo Alto Networks and Fortinet:

As you can see, Sourcefire and Fortinet have been longer term winners for investors while the short term performance for the latter has been flat verses the former.

The Bottom Line. If you are looking to speculate on more acquisitions in the IT security space, Palo Alto Networks and Fortinet would be good bets, but more conservative investors might want to stay away and stick to larger cap IT plays.

Tuesday, September 24, 2013

Treasuries Brace for 3-Percent 10-Year and 4-Percent 30-Year Yields

It is no secret now that interest rates have risen. Long-term Treasury yields and even intermediate Treasury yields are now perhaps even starting to normalize even with Ben Bernanke and the Federal Reserve keeping Fed Funds down at the 0.00% to 0.25% target rate. The problem that is going to startle longer-term bond investors is that the 10-year Treasury Note is getting closer and closer to 3% and the 30-year Treasury Bond is getting closer to 4%. We are seeing that the iShares Barclays 20+ Year Treasury Bond (NYSEMKT: TLT) and the ProShares UltraShort 20+ Year Treasury (NYSEMKT: TBT) are also starting to reach critical levels.

The question to ask is what happens when investors who own 10-year to 30-year noted and bonds realize that they have lost 5% to 10% (or slightly more) in their bond portfolios. Investors flocked to bonds as a safety net because stocks were too volatile, yet stocks have more than doubled off their lows and suddenly they are finding out that bonds come with risk too.

Monday brought on a rather dismal notion in rates. The 10-Year Treasury yield hit a high of 2.88% on Monday. The prior stop had been around 2.70%. On May 1 this yield was as lows at 1.61%, so now we have seen interest rates rise more than 1.25%. Keep in mind that the lowest 10-year yields of about 1.40% in July 2012 have now doubled.

The 30-year Treasury yield of 3.88% is up from a recent low of 2.81% at the start of May. The lowest yield back in 2012 was 2.45%. Now rates appear to be challenging 4%, which will have peeled off close to 15% of the face value of any Long Bond buyer who purchased when yields were at the lows.

If you do not believe that rates are killing bond values in retirement and investing portfolios, take a look. The iShares Barclays 20+ Year Treasury Bond (NYSEMKT: TLT) ETF hit a 52-week low of $102.49 on Monday. Its yield is 2.87%, but the 52-week high is $127.72. On May 1 that price was $123.12, so this ETF has lost almost 17% f its value in just over 100 days.

If you want the inverse of this, the inversely correlated and leveraged ProShares UltraShort 20+ Year Treasury (NYSEMKT: TBT) ETF hit a new 52-week high of $82.45 against a 52-week low of $58.23. The exchange-traded product closed at $58.49 on May 1. Because its price rises with yields and with all of the leverage, this exchange-traded product is up literally 40% since just the start of May.

What is happening is that the markets continue to brace for a tapering of the $85 billion per month in mortgage-backed securities and Treasury bonds by the Federal Reserve. It is interesting that this sell-off is coming at a time with very low participation in August and now that stocks have sold off for two weeks.

10 Best Casino Stocks To Buy Right Now

If you have been around through various interest rate cycles, you know that rates do not rise only over a very short period of time. Rates rise rapidly, and of course they ALWAYS rise too far. The problem that bond investors have to worry about is not just that the 10-year wants to challenge 3% and the 30-year wants to challenge 4%. The real worry is that the bear market in bonds is barely three months old, and of course mortgage rates are now up 100 basis points or more as well.

Some good news is possible. Municipal bonds are getting very cheap, ditto for junk bonds. REITs and high-yield bonds have been getting slammed as well. This will create some serious value for investors who can take a long-term opportunistic approach, but that opportunity may still be a ways off.

Monday, September 23, 2013

Food Stamps Again a Vivid Symbol in Poverty Debate

Food Stamps poverty americans shopping groceryMatt Rourke/AP WASHINGTON -- Food stamps have figured in Americans' ideas about the poor for decades, from President Lyndon Johnson's vision of a Great Society to President Ronald Reagan's scorn for crooked "welfare queens" and President Bill Clinton's pledge to "end welfare as we know it." Partisans tend to see what they want to see in the food stamp program: barely enough bread and milk to sustain hungry children, or chips and soda -- maybe even steak and illicit beer -- for cheaters and layabouts gaming the system. Those differences were on display Thursday when the House voted to cut almost $4 billion a year, or 5 percent, from the roughly $80 billion-a-year program. The House bill would tighten eligibility standards, allow states to impose new work requirements and permit drug testing for recipients, among other cuts to spending. A Senate bill would cut around one-tenth of the amount of the House bill, or $400 million a year. Republicans argued that work requirements target the aid to the neediest people. Democrats said the swelling rolls -- more than 47 million people are now using the food stamps, or 1 in 7 Americans -- show that the program is working at a time of high unemployment and great need. A look at the history and future of food stamps: No more Stamps These days, people in the nation's largest food aid program pay with plastic. These special debit cards are swiped at convenience store or supermarket checkouts to pay for groceries. The cards can't be used for alcohol or cigarettes or nonfood items such as toothpaste, paper towels or dog chow. Junk food or high-priced treats are OK. The first food stamps were a temporary plan to help feed the hungry toward the end of the Great Depression of the 1930s. The government subsidized the cost of blue stamps that poor people used to buy food from farm surpluses. The idea was revived in the 1960s and expanded under Johnson into a permanent program that sold food coupons to low-income people at a discount. Beginning in the 1970s, food stamps were given to the poor for free. Benefit cards began replacing paper in the 1980s, a move designed to reduce fraud and ease the embarrassment food stamp users felt at the cash register. Food stamps aren't the government's only way to feed those in need. There are more than a dozen smaller programs, including the one for Women, Infants and Children, and free and reduced-price school lunches. In 2008, food stamps were officially renamed the Supplemental Nutrition Assistance Program, or SNAP. Most people still know the name that's been familiar since 1939. One in Every 7 Americans In a nation of 314 million people, more than 47 million are eating with food stamps each month. Who are they? Children and teenagers make up almost half, according to the Agriculture Department. About 10 percent are seniors. The vast majority don't receive any cash welfare. Many households that shop with SNAP cards have someone who's employed but qualify for help because of low earnings. The average food stamp allotment is $133 a person per month. The monthly amount a family gets depends on the household's size, earnings and expenses, as well as changing food prices and other factors. Households can qualify for help with earnings up to 30 percent higher than the federal poverty level, making the limit about $30,000 for a family of four this year. These households are limited to no more than $2,000 in savings, or $3,250 if there are elderly or disabled residents. In addition, most states allow people to qualify automatically for food stamps if they are eligible for certain other welfare programs, even if they don't meet the strict SNAP standards. Although food stamps are paid for with federal tax dollars, states administer the program and have some choices in setting requirements. Language in Clinton's 1996 welfare overhaul required able-bodied adults who aren't raising children to work or attend job training or similar programs to qualify for food stamps after three months. But those work requirements across most of the nation have been waived for several years because of the high unemployment rate. People who are living in the United States illegally aren't eligible for food stamps. Most adults who immigrate legally aren't eligible during their first five years in the country. Rising Like Yeast The cost to taxpayers more than doubled over just four years, from $38 billion in 2008 to $78 billion last year. Liberals see a program responding to rising need at a time of economic turmoil. Conservatives see out-of-control spending, and many Republicans blame President Barack Obama. While seeking the GOP presidential nomination in 2012, Newt Gingrich labeled Obama the "food stamp president." Some of the growth can be attributed to Obama's food stamp policies, but Congress' budget analysts blame most of it on the economy. The big factors: The SNAP program is an entitlement, meaning everyone who is eligible can get aid, no matter the cost to taxpayers. Millions of jobs were lost in the recession that hit in 2007. Unemployment is still high, and many people who have jobs are working fewer hours or for lower pay than before, meaning more people are eligible. Obama's 2009 economic stimulus temporarily increased benefit amounts; that boost is set to expire on Nov. 1. Time limits for jobless adults without dependents are still being waived in most of the country. Food stamp eligibility requirements were loosened by Congress in 2002 and 2008, before Obama became president. Fluctuating food prices have driven up monthly benefit amounts, which are based on a low-cost diet. Fewer to Feed? The number of people using food stamps appears to be leveling off this year, and long-term budget projections suggest the number will begin to fall as the economy improves. Why is it taking so long? Although the jobless rate has dropped from its 2009 peak, it remains high, leaving a historically large number of people eligible for food stamps. Since the recession began, a bigger portion of people who are eligible have signed up for food stamps than in the past. Many people who enrolled during the worst days of the recession still qualify for SNAP cards, even if they are doing a little better now. For example, they may have gone from being laid off to working a low-paying or part-time job. The Congressional Budget Office predicts in about a decade the number of people using food stamps will drop to 34 million, or about 1 in every 10 people. Food and Fraud Abuse was a worry from the start. The 1939 food stamp program was launched in May and by that October a retailer had been caught violating the rules. There's been progress along the way, especially after the nationwide adoption of SNAP cards, which are harder to sell for cash than paper coupons were. The government says such "trafficking" in food stamps has fallen significantly over the past two decades, from about 4 cents on the dollar in 1993 to a penny per dollar in 2008. But many lawmakers say fraud is still costing taxpayers too much. Some people lie about their income, apply for benefits in multiple states or fail to quit the program when their earnings go up. Recipients must tell their state agency within 10 days if their income goes over the limit. Some stores illegally accept food stamps to pay for other merchandise, even beer or electronics, or give out cash at a cut rate in exchange for phony food purchases, which are then reimbursed by the government. Food and Farms In Congress, it's a marriage of convenience. Food stamp policy has been packaged in the same bill with farm subsidies and other agricultural programs since the 1970s. It was a canny way of assuring that urban lawmakers who wanted the poverty program would vote for farm spending. That worked until this year, when conservatives balked at the skyrocketing cost of food stamps. In June, a farm bill that included food stamps was defeated in the Republican-led House because fiscal conservatives felt it didn't cut the program deeply enough. In response, GOP leaders split the food and farm programs in two. The House passed the farm version in July and the food stamp version on Thursday. Both passed with narrow votes. The House and Senate versions must be reconciled before the five-year farm bill can become law, and that won't be an easy task. Food stamps remain in the farm bill passed by the Senate. That bill made only a half-percent cut to food stamps and the Democratic-led Senate will be reluctant to cut more deeply or to evict the poverty program from its home in the farm bill. Obama supported the cuts in the Senate bill, but has opposed any changes beyond that. The White House threatened to veto the House food stamp bill. What Now? The current farm and food law expires at the end of the month. If the two sides can't agree by then, a likely scenario, Congress could vote to extend the law as it is, at the expense of many planned updates to agricultural policy. There won't be much urgency to do that until the end of the year, when some dairy supports expire and milk prices could rise. Other farm supports won't expire until next year, but farmers have been frustrated with the drawn-out debate that has now lasted two years, saying they need more government certainty as they manage their farm operations. SNAP benefits would still be available for now. While farm bills set food stamp policy, the money is paid out through annual appropriations bills that so far have left benefits intact.

Top 5 Gold Companies To Own For 2014

Mint made the Mac App Store's Best of 2012 list for a reason. This simple, clean app shows how much you are spending in each category of your budget by monitoring all of your transactions. We love signing in and getting a quick, dirty rundown of where our money has gone over the last week, and using their personalized budget tools to stay on track. We highly recommend adjusting your budgets for summer months. You might spend less on transportation when the weather is nice, and chances are you could use that extra cash to flesh out that restaurant tab, right?

Price: Free

Thursday, September 19, 2013

Top Medical Stocks To Own Right Now

It's a bit incongruous, but industrial manufacturing specialist Roper� (NYSE: ROP  ) is now the proud owner of Managed Health Care Associates, a New Jersey-based supplier of services for�alternate site health-care providers.�The transaction was valued at approximately $1 billion, and was funded from Roper's�available cash and borrowings under its credit facility.

MHCA�negotiates discounted contracts with pharmaceutical manufacturers and medical equipment suppliers on behalf of nursing home operators, or assisted living facilities that operate outside of a traditional hospital setting.

When the deal was announced last month,�Roper's Chairman, President and CEO�Brian Jellison said:

MHA's powerful technology tools and proven customer-service model continue to drive growth in their multiple niches. The company has attractive cash return characteristics and generates substantial recurring revenue through long-term customer relationships and very high retention rates.

Top Medical Stocks To Own Right Now: Prima BioMed Ltd (PRR)

Prima BioMed Ltd is a biotechnology company is engaged in the development and commercialization of medical therapies with a focus on oncology. Its product candidates in development include Cvac, an autologous dendritic cell vaccine for ovarian cancer, monoclonal antibodies for multiple tumour types, and an oral formulation for the human papilloma virus (HPV), vaccine. Its product candidate Cvac is a dendritic cell therapy, for which it is conducting a Phase IIb trial for the treatment of ovarian cancer. Cvac is designed to target the tumour antigen mucin-1, which is expressed at high levels on different tumour types. It also has two preclinical product development programs. In May 2011, Prima BioMed GmbH, a 100 % owned subsidiary of Prima BioMed Ltd, was incorporated in Germany. In May 2011, Prima BioMed Middle East FZLLC, a 100 % owned subsidiary of Prima BioMed Ltd, was incorporated in the United Arab Emirates.

Top Medical Stocks To Own Right Now: NeoStem Inc (NBS)

NeoStem, Inc., incorporated on September 18, 1980, operates in cellular therapy industry. Cellular therapy addresses the process by which new cells are introduced into a tissue to prevent or treat disease, or regenerate damaged or aged tissue, and consists of a separate therapeutic technology platform in addition to pharmaceuticals, biologics and medical devices. The Company�� business model includes the development of novel cell therapy products, as well as operating a contract development and manufacturing organization (CDMO) providing services to others in the regenerative medicine industry. Progenitor Cell Therapy, LLC, the Company�� wholly owned subsidiary (PCT), is a CDMO in the cellular therapy industry. PCT has provided pre-clinical and clinical current Good Manufacturing Practice (cGMP) development and manufacturing services to over 100 clients advancing regenerative medicine product candidates through rigorous quality standards all the way through to human testing.

PCT has two cGMP, cell therapy research, development, and manufacturing facilities in New Jersey and California, serving the cell therapy community with integrated and regulatory compliant distribution capabilities. Its core competencies in the cellular therapy industry include manufacturing of cell therapy-based products, product and process development, cell and tissue processing, regulatory support, storage, distribution and delivery and consulting services. The Company�� wholly-owned subsidiary, Amorcyte, LLC (Amorcyte) is developing its own cell therapy, AMR-001, for the treatment of cardiovascular disease. AMR-001 represents its clinically advanced therapeutic product candidate and enrollment for its Phase II PreSERVE clinical trial to investigate AMR-001's safety and efficacy in preserving heart function after a heart attack in a particular type of post Acute Myocardial Infarction (AMI) patients.

Through the Company�� subsidiary, Athelos Corporation (Athelos), the Company is collaborating w! ith Becton-Dickinson in early stage clinical development of a therapy utilizing T-cells, collaborating for autoimmune and inflammatory conditions, including but not limited to, graft vs. host disease, type 1 diabetes, steroid resistant asthma, lupus, multiple sclerosis and solid organ transplant rejection. The Company�� pre-clinical assets include its Very Small Embryonic Like (VSEL) Technology platform. The Company has basic research and development capabilities, manufacturing facilities on both the east and west coast of the United States.

Top Growth Stocks For 2014: Scancell Holdings PLC (SCLP)

Scancell Holdings PLC is a United Kingdom-based company. The Company�� principal activity of the consists of the discovery and development of monoclonal antibodies and vaccines for the treatment of cancer. In April 2012, the Company completed recruitment to the Phase 1 clinical trial of SCIBI. In May 2012, the Company commenced recruitment and treatment of the first patient in the second part of it Phase 1/2 clinical trial of SCIBI. The Phase 2 part of the trial is conducted in five United Kingdom centers in Nottingham, Manchester, Newcastle, Leeds, and Southampton. On August 15, 2012, the Company announced the development of a platform technology, Moditope.

Top Medical Stocks To Own Right Now: RXi Pharmaceuticals Corp (RXII)

RXi Pharmaceuticals Corporation (RXi), incorporated on September 8, 2011, is a development-stage company. The Company is a biotechnology company focused on discovering, developing and commercializing therapies addressing medical needs using RNA interference (RNAi)-targeted technologies. As of July 12, 2012, RXi was focusing on its internal therapeutic development efforts in fibrosis. RXI-109 is its RNAi product candidate, which is a dermal anti-scarring therapy that targets connective tissue growth factor (CTGF). The Company�� therapeutic platform consists of two main components: RNAi Compounds (rxRNA) and Advanced Delivery Technologies. RNAi compounds include rxRNAori, rxRNAsolo and sd-rxRNA, or self-delivering RNA. On April 26, 2012, it completed the spin-off transaction from Galena Biopharma, Inc. (Galena).

In January 2011, the Company announced research results in collaboration with Generex Biotechnology Corporation, and RXi�� wholly owned subsidiary Antigen Express, Inc., in developing vaccine formulations for immunotherapy. In January 2011, it announced initial results as part of its collaboration with miRagen Therapeutics, Inc. in creating microRNA mimics, or artificial copies of microRNAs, using the Company�� sd-rxRNA technology. In February 2011, it announced the initiation of RXi�� development program for RXI-109.

Top Medical Stocks To Own Right Now: Scancell Holdings PLC (SCLP.L)

Scancell Holdings PLC is a United Kingdom-based company. The Company�� principal activity of the consists of the discovery and development of monoclonal antibodies and vaccines for the treatment of cancer. In April 2012, the Company completed recruitment to the Phase 1 clinical trial of SCIBI. In May 2012, the Company commenced recruitment and treatment of the first patient in the second part of it Phase 1/2 clinical trial of SCIBI. The Phase 2 part of the trial is conducted in five United Kingdom centers in Nottingham, Manchester, Newcastle, Leeds, and Southampton. On August 15, 2012, the Company announced the development of a platform technology, Moditope.

Top Medical Stocks To Own Right Now: Rexahn Pharmaceuticals Inc (RNN)

Rexahn Pharmaceuticals, Inc. (Rexahn) is a development-stage biopharmaceutical company. The Company focuses on the development of cures for cancer to patients worldwide. The Company�� pipeline features one drug candidate in Phase II clinical trials. The Company also has several other drug candidates in pre-clinical development. In addition, the Company has two renal cell carcinoma (CNS) candidates, Serdaxin, CNS Disorders drug for depression and neurodegenerative diseases and Zoraxel, which is a erectile dysfunction (ED) and sexual dysfunction drug that are in clinical stages and the Company is are exploring options for further development . The Company�� drug candidate, Archexin is an anticancer Akt inhibitor.

Archexin

Archexin is potent inhibitor of the Akt protein kinase (Akt) in cancer cells. Archexin has FDA orphan drug designations for five cancers (RCC, glioblastoma, and cancers of the ovary, stomach and pancreas). Multiple indications for other solid tumors can also be pursued. Archexin inhibit both activated and inactivated forms of Akt, and to reverse the drug resistance observed with the protein kinase inhibitors. Archexin is an antisense oligonucleotide (ASO) compound that is complementary to Akt mRNA, and selective for inhibiting mRNA expression and production of Akt protein. As of December 31, 2011, Archexin was in Phase II clinical trials for the treatment of pancreatic cancer with enrollment completed in September, 2011.

Serdaxin

Serdaxin is an extended release formulation of clavulanic acid, which is an ingredient present in antibiotics approved by the FDA. The Company had been developing Serdaxin for the treatment of depression and neurodegenerative disorders. From January to September, 2011, the Company conducted a randomized, double-blind, placebo-controlled study compared two doses of Serdaxin, 0.5 milligram and 5 milligram, to placebo over an eight-week treatment period for major depressive disorder (MDD) patients. As of Dec! ember 31, 2011, the Company had not made a determination of Serdaxin�� future paths or resource allocations to further develop Serdaxin to treat MDD.

Zoraxel

Zoraxel is an orally administered, on-demand tablet to treat sexual dysfunction. Zoraxel is a dual enhancer of neurotransmitters in the brain that play a key role in sexual activity phases of motivation and arousal, erection and release, and may be the ED drug to affect all three of these phases of sexual activity. As of December 31, 2011, the Company was evaluating how to proceed with the Phase IIb study of Zoraxel.

The Company�� Pre-clinical Pipeline Drug Candidates includes RX-1792, which is a small molecule anticancer EGFR inhibitor; RX-5902, which is a small molecule anticancer ribonucleic acid (RNA) helicase regulator; RX-3117, which is a Small molecule anticancer deoxyribonucleic acid (DNA) synthesis Inhibitor; RX-8243, which is a small molecule anticancer aurora kinase inhibitor; RX-0201-Nano, which is a nanoliposomal anticancer Akt inhibitor; RX-0047-Nano, which is an nanoliposomal anticancer HIF-1 alpha inhibitor and RX-21101, which is a nano-polymer Anticancer.

Top Medical Stocks To Own Right Now: Elan Corporation PLC (ELN)

Elan Corporation, plc (Elan), incorporated in December 1969, is a neuroscience-based biotechnology company. The Company is focused on discovering and developing advanced therapies in neurodegenerative and autoimmune diseases. Elan�� business focuses on neurodegenerative diseases, such as Alzheimer�� disease and Parkinson�� disease; autoimmune diseases, including MS and Crohn�� disease and neo-epitope based targets for treatments across a range of therapeutic indications. Tysabri is a treatment for MS and Crohn�� disease that the Company markets and distributes with Biogen Idec. On September 16, 2011, Elan sold its EDT business to Alkermes, Inc. In November 2011, Elan launched a collaboration with the University of Cambridge, England, the Cambridge-Elan Centre for Research Innovation and Drug Discovery (Cambridge-Elan Centre). On December 21, 2012, the Company completed the demerger of Prothena Corporation plc. In April 2013, it closed the TYSABRI (natalizumab) Collaboration Transaction with Biogen Idec.

Tysabri

Tysabri, which is an alpha-4 integrin inhibitor, is a therapy for MS, a neurological disorder involving central nervous system dysfunction among adults. Tysabri is approved in more than 65 countries. Tysabri is approved in the United States as a monotherapy for relapsing forms of MS, for patients who have had an inadequate response to, or are unable to tolerate, an alternative MS therapy. In the European Union, it is approved for relapsing-remitting MS (RRMS) in adult patients who have failed to respond to beta interferon or have rapidly evolving, severe RRMS. As of December 31, 2011, there were approximately 64,400 patients on Tysabri therapy worldwide.

In June 2011, the European Commission (EC) approved the inclusion of the anti-JCV antibody status as an additional factor in stratifying patients at risk for developing PML in the Summary of Product Characteristics��(SmPC) for Tysabri in the European Union. The Company has developed a two-step ! enzyme-linked immunosorbent assay (ELISA), STRATIFY JCV, with Biogen Idec. The assay detects anti-JCV antibodies in the blood of patients, and is commercially available in Europe. In January 2012, the FDA cleared the assay for commercial use in the United States. As of December 31, 2011, over 80,000 tests had been administered using the assay. Tysabri is marketed and distributed by Elan and Biogen Idec. The Company�� research group, Neotope, is focused on creating monoclonal antibodies based on neo-epitope targets for the treatment of a range of therapeutic indications.

Beta Amyloid Immunotherapies (AIP)

Beta amyloid immunotherapy includes the treatment of Alzheimer�� disease by inducing or enhancing the body�� immune response in order to clear toxic species of beta amyloid from the brain. The AIP includes bapineuzumab (intravenous and subcutaneous delivery) and ACC-001, as well as other compounds. Bapineuzumab is an experimental humanized monoclonal antibody delivered intravenously that is being studied as a treatment for mild to moderate Alzheimer�� disease. It is designed to provide antibodies to beta amyloid directly to the patient (passive immunotherapy).

ELND005, an A� Aggregation Inhibitor

The small molecule ELND005 (Scyllo-inositol) is a beta amyloid anti-aggregation agent. Preclinical data suggest that ELND005 may act through the mechanism of preventing and reversing the fibrilisation of beta amyloid (the aggregation of beta amyloid into clumps of insoluble oligomers). ELND005 may have additional applications in psychiatric indications, such as bipolar disorder. In November 2011, the Company entered into a manufacturing agreement for the supply of the active pharmaceutical ingredient for ELND005 with Lonza Group AG.

Neotope Biosciences Limited

Neotope Biosciences Limited (Neotope) is the Company�� wholly owned subsidiary that focuses on the discovery and development of antibodies to neo-epitope related targ! ets for t! he treatment of a range of indications. It includes amyloidosis, diabetes, cancer and macular degeneration. Neotope�� portfolio of targets includes alpha-synuclein for the potential treatment of synucleinopathies, such as Lewy body dementia and Parkinson�� disease, tau for Alzheimer�� disease and other tauopathies. It also has a program for type 2-diabetes.

Onclave Therapeutics Limited

Elan�� wholly owned subsidiary Onclave Therapeutics Limited (Onclave) was formed to develop assets originating from Elan that have application in oncology related diseases. Onclave�� program, NEOD001, which originated from Neotope, is being investigated for the treatment of AL amyloidosis, which is a fatal disease involving abnormal accumulation of amyloid in organs and tissue. During the year ended December 31, 2011, Onclave filed for orphan drug designation of NEOD001. Onclave�� pipeline includes additional compounds with relevance in diverse cancer indications.

The Company competes with Biogen Idec, Bayer Schering Pharma AG, Bayer Schering Pharma, Merck Serono, Pfizer, Teva Neurosciences, Inc., Sanofi-Aventis and Novartis AG.

Top Medical Stocks To Own Right Now: Spectrum Pharmaceuticals Inc.(SPPI)

Spectrum Pharmaceuticals, Inc., a commercial-stage biotechnology company, primarily focuses on oncology and hematology. The company engages in acquiring, developing, and commercializing a broad and diverse pipeline of late-stage clinical and commercial products. It markets Zevalin, a prescribed form of cancer therapy, radioimmunotherapy; and Fusilev, a novel folate analog formulation and the pharmacologically active isomer of the racemic compound, calcium leucovorin. The company?s drugs in late stage development include Apaziquone, an anti-cancer agent; and Belinostat, a histone deacytelase inhibitor. Its drugs in development also include Ozarelix a luteinizing hormone releasing hormone antagonist, which is in Phase II clinical stage; SPI-1620, a peptide agonist of endothelin B receptors, which is in Phase I clinical stage; and RenaZorb, a lanthanum-based nanoparticle phosphate binding agent, which is in preclinical stage. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was founded in 1987 and is based in Henderson, Nevada.

Monday, September 16, 2013

J.P. Morgan Highlights More Options Than Ever to Upgrade Your Smartphone

With the next generation of the iconic iPhone from Apple Inc. (NASDAQ: AAPL) imminent and a huge introduction expected to be announced from Cupertino next week, a myriad of new early upgrade programs are being offered. The telecom services analysts at J.P Morgan have taken a long look at ways that customers who are on/off-contract can upgrade to the latest and greatest smartphones. Obviously, customers on contracts that are not yet eligible for subsidized devices will have to pay more to upgrade. At least there are more options than ever to offset the increased cost by trading in (relatively new) old smartphones. Depending on the device and condition, customers can generally look to get at least $100 to upwards of $350 from trading in their old smartphones. Here are the top places for consumers to trade in and trade up to a new smartphone.

Gazelle is a private company to which you can sell your smartphone, iPad, iPod, even a Mac computer or Macbook. While it does not offer the best trade-in values, the sheer number of devices the company will buy makes it a great place for consumers to start looking.

Amazon.com Inc. (NASDAQ: AMZN) continues to offer a fantastic a trade-in program on recent iPhone models (3GS, 4, 4S and 5) and offers the best value for your trade-in. They offer on average $337 for the iPhone 5 16GB (in "good" condition) vs. Gazelle's and Apple's average offers of $312 (excluding the Sprint version) and $309, respectively. The downside is your payment only comes as an Amazon gift card. Plus, they only offer trade-ins for Apple iPhones and not other smartphones. Customers do get free shipping.

Apple's trade-in program, which was launched late last month, has better prices than Gazelle, but not as good as Amazon. Customers can trade in any old iPhone for an Apple gift card at an Apple store or online with free shipping. Again, there are limitations like the Amazon offer, as you only can get the Apple gift card. However, it is a great plan for the Apple aficionado looking to trade up to a new iPhone. Apple does not accept any other smartphones on trade except their product.

AT&T Inc. (NYSE: T) offers a trade-in program, but it seems to require more personal information before offering a price, so the actual pricing offered is harder to be sure of. The company website lists a host of devices that you can trade in, but it is likely that only iPhones and the latest high-end Android smartphones will have any substantial trade-in values. The AT&T Next plan allows for a new smartphone or tablet every 12 months with "no fees." A monthly installment plan payment is added to your bill.

Best Clean Energy Stocks To Own For 2014

Sprint Corp. (NYSE: S) has a trade-in program that really only gives the seller an account credit, which is great if you are an existing customer or looking to switch to the carrier. Like the other carriers, the value for your trade-in will be much higher at Gazelle, Amazon or Apple.

Verizon Communications Inc. (NYSE: VZ) program pretty much mirrors the AT&T and Sprint programs. It gives customers a Verizon gift card in exchange for the trade-in. Again, for existing customers or those looking to move to the carrier this may make sense. As in the other cases, consumers will receive more from the non-carrier locations.

Global system for mobile communications (GSM) devices, which are the ones that can operate on the AT&T and T-Mobile US INC. (NYSE: TMUS) networks, tend to have a higher resale value than the code division multiple access (CDMA) devices that work on Verizon and Sprint’s networks. This is because GSM models generally can be used everywhere overseas where the majority of the carriers use the GSM standard.

Smartphone use has become ubiquitous, and consumers do not want to be locked in to devices that will be less than the gold standard in less than a year. The carriers, retailers and the companies that make the products have all acknowledged this and are competing for your trade-in. The real question is what is the easiest and most cost-efficient way? The answer to that probably will change as fast as the smartphones do.

By now you certainly have seen that the wireless and telecom industry has consolidated into mostly a few major players. Here is a list of possible acquisition candidates that could still be acquired, along with some that likely cannot be.

Saturday, September 14, 2013

Will Delta Reach New Heights?

With shares of Delta Air Lines Inc. (NYSE:DAL) trading at around $17.49, is DAL an OUTPERFORM, WAIT AND SEE or STAY AWAY? Let's analyze the stock with the relevant sections of our CHEAT SHEET investing framework:

C = Catalyst for the Stock's Movement

Delta was given an OUTPERFORM rating here on March 5, but have circumstances changed?

Delta serves over 160 million customers per year. Despite that fact, the competition is always fierce. And fuel costs are an even bigger concern (has been approximately 37 percent of costs). However, as we all know by now, Delta made an unprecedented move by buying its own oil refinery. This was a risky move, but if it works out, then it's going to be a home run.

Customer satisfaction has also been a focus for Delta. The airline has done everything in its power to make passenger experiences more comfortable and enjoyable. And Delta still isn't done. It's constantly attempting to find creative ways to improve passenger experience. Passengers might not be happy about the increase in lounge membership, but investors won't mind.

Delta and debt have gone hand-in-hand for many years. While this is still a concern, Delta has been focused on debt reduction. This will be covered further on the next page.

Other positives for Delta include capacity discipline and better resiliency than most peers in past bear markets. However, it's not resilient. Airlines as a whole don't hold up well when market conditions worsen.

The company culture at Delta is strong. At Glassdoor.com, employees have rated it a 3.3 of 5, which is high for the airline industry and above average in general. A respectable 65 percent of employees would recommend the company to a friend, and a somewhat impressive 74 percent of employees approve of CEO Richard H. Anderson. For a comparison, employees at US Airways Group (NYSE:LCC) have rated its employer at 2.9 of 5. An average 50 percent of employees would recommend the company to a friend, and 69 percent approve of CEO Doug Parker. For one more comparison, employees at United Continental Holdings (NYSE:UAL) have rated its employer at 2.9 of 5. An unimpressive 41 percent of employees would recommend the company to a friend. However, 72 percent of employees approve of CEO Jeffrey A. Smisek. There's a disconnect at United somewhere, but that's a story for another time.

Now let's take a look at some comparative numbers. The chart below compares fundamentals for Delta, US Airways, and United. Delta has a market cap of $14.62 billion, US Airways has a market cap of $2.76 billion, and United has a market cap of $10.85 billion.

NEW! Discover a new stock idea each week for less than the cost of 1 trade. CLICK HERE for your Weekly Stock Cheat Sheets NOW!

DAL

LCC

UAL

Trailing   P/E

16.45

5.20

N/A

Forward   P/E

5.51

5.50

6.55

Profit   Margin

2.43%

4.54%

-1.86%

ROE

N/A

121.61%

N/A

Operating   Cash Flow

$2.65 Billion

$1.00 Billion

 N/A

Dividend   Yield

N/A

N/A

N/A

Short   Position

0.90%

32.20%

7.80%

 

Let's take a look at some more important numbers prior to forming an opinion on this stock.

E = Equity to Debt Ratio Is Not Available  

Top Penny Stocks To Own For 2014

The debt-to-equity ratio for Delta is unavailable. However, as far as the balance sheet is concerned, cash has been increased from $3.37 billion to $3.60 billion, and long-term debt has been decreased from $13.24 billion to $12.99 billion.

Debt-To-Equity

Cash

Long-Term Debt

DAL

N/A

$3.60 Billion

$12.99 Billion

LCC

5.82

$2.53 Billion

$4.89 Billion

UAL

27.37

$6.54 Billion

$13.17 Billion

 

T = Technicals Are Strong    

Delta has outperformed US Airways and United year-to-date.

NEW! Discover a new stock idea each week for less than the cost of 1 trade. CLICK HERE for your Weekly Stock Cheat Sheets NOW!

1 Month

Year-To-Date

1 Year

3 Year

DAL

7.66%

47.39%

58.33%

44.83%

LCC

1.50%

25.33%

66.54%

139.30%

UAL

5.23%

39.39%

48.74%

50.90%

 

At $17.49, Delta is trading above all its averages.

50-Day   SMA

15.64

100-Day   SMA

14.29

200-Day   SMA

11.94

 

E = Earnings Have Steady                    

Earnings and revenue have both steadily improved on an annual basis.

2008

2009

2010

2011

2012

Revenue   ($)in   billions

22.70

28.06

31.76

35.12

36.67

Diluted   EPS ($)

-19.08

-1.50

0.70

1.01

1.19

 

When we look at the last quarter on a year-over-year basis, we see an increase in revenue, but a decline in earnings.

3/2012

6/2012

9/2012

12/2012

3/2013

Revenue   ($)in   billions

8.41

9.73

9.92

8.60

8.50

Diluted   EPS ($)

0.15

-0.20

1.23

0.01

0.01

 

Now let's take a look at the next page for the Trends and Conclusion. Is this stock an OUTPERFORM, a WAIT AND SEE, or a STAY AWAY?

T = Trends Might Support the Industry

Oil has been dropping, which is good news for the airlines. However, demand for leisure travel isn't likely to remain strong. The consumer has an uphill battle considering tax hikes, current unemployment and underemployment, many companies now cutting employees to improve their bottom lines, the possibility of entitlement cuts, and more. It should also be noted that consumers have $2.4 trillion in debt. That's with a "T".

NEW! Discover a new stock idea each week for less than the cost of 1 trade. CLICK HERE for your Weekly Stock Cheat Sheets NOW!

Conclusion

Delta was ahead of the curve by purchasing an oil refinery. Other positives for Delta include improve improvements in debt management, revenue and earnings improvements on an annual basis, and a strong company culture. The big concern is the consumer. While Wall Street is enjoying the best time of its life, the average Main Street individual is attempting to figure out a way to survive. The dilemma here is that over the long haul, Delta needs the Main Street consumer in order to thrive.

Tuesday, September 10, 2013

Is Electronic Arts Really the Worst Company in America?

With shares of Electronic Arts Inc. (NASDAQ:EA) trading at around $22.80, is EA an OUTPERFORM, WAIT AND SEE or STAY AWAY? Let's analyze the stock with the relevant sections of our CHEAT SHEET investing framework:

C = Catalyst for the Stock's Movement

To immediately answer the question in the title, absolutely not. EA might have had several missteps over the past several years, and it's no secret that revenue has been a major problem, but the worst company in the world doesn't have a positive profit margin, a strong balance sheet, increased revenue guidance, a decent product pipeline, increased online exposure, increased social and mobile exposure, consistent annual earnings improvements, and a 75 percent increase in the stock price over the past year.

The big news for Electronic Arts right now is Fuse, which is a sci-fi shooter. The PS3 and Xbox 360 versions of Fuse have received mixed reviews. Below is a very quick breakdown of the most commonly reported positives and negatives:

NEW! Discover a new stock idea each week for less than the cost of 1 trade. CLICK HERE for your Weekly Stock Cheat Sheets NOW!

Positives:

Weapons

Co-Op Action

Negatives

Team A.I.

Confusing Tone

Yeah, that was quick. In regards to weapons, gamers have greatly appreciated the creativity, such as a mag shield that can absorb bullets and then fire them back at enemies.

While Fuse's potential success is still a guessing game, there is no doubt that Electronic Arts landing a deal with The Walt Disney Company (NYSE:DIS) for video gaming rights to Star Wars was a big splash. Star Wars has been a massively popular franchise for decades. What most people don't realize is that the franchise still has potential to grow, especially under Disney's leadership.

Electronic Arts is facing competition from free-to-play games, but its PopCap Games is now offering Plants vs. Zombies Adventures on Facebook (NASDAQ:FB). This is free-to-play, but in-game items are being sold. Other PopCap Games include Bejeweled, Bookworm, and Zuma. There are 42 other games as well.

The chart below takes a look at some basic fundamentals for Electronic Arts, Activision Blizzard (NASDAQ:ATVI), and Take-Two Interactive Software (NASDAQ:TTWO).

EA ATVI TTWO
Trailing P/E 74.10 13.21 N/A
Forward P/E 16.29 13.92 15.09
Profit Margin 2.58% 24.38% -2.43%
ROE 4.15% 11.09% -5.27%
Operating Cash Flow 324.00M 1.52B -4.57M
Dividend Yield N/A 1.30% N/A
Short Position 5.30% 1.90% 17.40%

Let's take a look at some more important numbers prior to forming an opinion on this stock.

T = Technicals Are Strong

For the worst company in the world, Electronic Arts sure is beating expectations when it comes to stock performance.

NEW! Discover a new stock idea each week for less than the cost of 1 trade. CLICK HERE for your Weekly Stock Cheat Sheets NOW!
1 Month Year-To-Date 1 Year 3 Year
EA 27.60% 57.78% 75.29% 44.91%
ATVI -6.39% 35.56% 23.58% 38.56%
TTWO 2.93% 46.59% 48.07% 46.33%

At $22.80, Electronic Arts is trading above its averages.

50-Day SMA 20.13
200-Day SMA 17.16

E = Equity to Debt Ratio Is Strong

The debt-to-equity ratio for Electronic Arts is stronger than the industry average of 0.30.

Debt-To-Equity Cash Long-Term Debt
EA 0.25 1.68B 559.00M
ATVI 0.00 4.62B 0.00
TTWO 0.57 402.50M 335.20M

E = Earnings Have Improved

Top Stocks To Buy For 2014

Earnings have consistently improved on an annual basis. However, revenue has been very inconsistent.

Fiscal Year 2009 2010 2011 2012 2013
Revenue ($) in millions 4,212 3,654 3,589 4,143 3,797
Diluted EPS ($) -3.40 -2.08 -0.84 0.23 0.31

Looking at the last quarter on a year-over-year basis, revenue and earnings both declined. On the other hand, revenue and earnings made substantial improvements on a sequential basis.

Quarter Mar. 31, 2012 Jun. 30, 2012 Sep. 30, 2012 Dec. 31, 2012 Mar. 31, 2013
Revenue ($) in millions 1,368 955 711 922 1,209
Diluted EPS ($) 1.20 0.63 -1.21 -0.15 1.05

Now let's take a look at the next page for the Conclusion. Is this stock an OUTPERFORM, a WAIT AND SEE, or a STAY AWAY?

Conclusion

Investors are frustrated with Electronic Arts due to its inability to come up with new titles. Retail gaming sales have also been weak. Another negative is that Electronic Arts is trading at 74 times earnings whereas the industry average is only 7 times earnings. That said, all the positives mentioned earlier should also be considered.

Monday, September 9, 2013

Hot Biotech Stocks To Watch Right Now

It may seem like an easy question to answer, but determining what the largest pharmaceutical company in the world is can be trickier than it looks. The definition of what a "pharmaceutical company" actually is has been changing in the past few years. Some companies, such as Pfizer (NYSE: PFE  ) and AbbVie, focus on developing and selling branded drugs, while others, such as Johnson & Johnson (NYSE: JNJ  ) and Merck, have a different strategy and are much more diversified.

So what is a pharmaceutical company, and which one is the largest in the world today? Health-care analyst Max Macaluso weighs in on this debate in the following video.

Is bigger really better?
The biggest pharmaceutical company may not be the best investment. Involved in everything from baby powder to biotech, Johnson & Johnson has its critics convinced that the company is spread way too thin. If you want to know whether J&J is nothing but a bloated corporate whale -- or a well-diversified giant that's perfect for your portfolio -- check out the Fool's new premium report outlining the Johnson & Johnson story in terms that any investor can understand. Claim your copy by clicking here now.�

Hot Biotech Stocks To Watch Right Now: Galena Biopharma Inc (GALE.PH)

Galena Biopharma, Inc. (Galena), formerly RXi Pharmaceuticals Corporation, incorporated on April 3, 2006, is a biotechnology company focused on discovering, developing and commercializing therapies addressing unmet medical needs using targeted biotherapeutics. The Company is pursuing the development of cancer therapeutics using peptide-based immunotherapy products, including its main product candidate, NeuVaxTM (E75), for the treatment of breast cancer and other tumors. NeuVax is a peptide-based immunotherapy intended to reduce the recurrence of breast cancer in low-to-intermediate HER2-positive breast cancer patients not eligible for trastuzumab (Herceptin; Genentech/Roche). On January 19, 2012, the Company initiated enrollment in its Phase 3 PRESENT clinical trial for NeuVax (E75 peptide plus GM-CSF) vaccine in low-to-intermediate HER2 1+ and 2+ breast cancer patients in the adjuvant setting to prevent recurrence (Clinicaltrials.gov identifier NCT01479244). The Preven tion of Recurrence in Early-Stage, Node-Positive Breast Cancer with Low to Intermediate HER2 Expression with NeuVax Treatment study is a randomized, multicenter, multinational clinical trial that will enroll approximately 700 breast cancer patients. The Company�� Phase 2 trial of NeuVax achieved its primary endpoint of disease-free survival (DFS). On April 13, 2011, the Company completed its acquisition of Apthera, Inc.,(Apthera).

The Company focuses to start a Phase 2 trial comparing NeuVax in combination with trastuzumab (Herceptin) versus trastuzumab, alone, in a 300-patient, randomized study in the adjuvant breast cancer setting. The Company's second product candidate, Folate Binding Protein-E39 (FBP), is a vaccine, consisting of the peptides E39 and J65, aimed at preventing the recurrence of ovarian, endometrial, and breast cancers. On February 14, 2012, the Company announced the initiation of a Phase 1/2 clinical trial in two gynecological cancers: ovari an and endometrial adenocarcinomas. Folate binding protein! h! as very limited tissue distribution and expression in non-malignant tissue and is over-expressed in more than 90% of ovarian and endometrial cancers, as well as in 20% to 50% of breast, lung, colorectal and renal cell carcinomas.

In April 2011, the Company acquired Apthera Inc and its NeuVax product candidate. The Company focuses on developing a pipeline of immunotherapy product candidates for the treatment of various cancers based on the E75 peptide, the advanced of which is NeuVax, which is targeted at preventing the recurrence of breast cancer. NeuVax has had positive Phase 1/2 clinical trial results for the prevention of breast cancer recurrence in patients who have had breast cancer and received the standard of care treatment (surgery, chemotherapy, radiotherapy and hormonal therapy as indicated). The Company had also initiated its Phase 3 PRESENT clinical trial of NeuVax for the prevention of breast cancer recurrence in early-stage low-to-intermediate HER2 breast cancer patients. NeuVax directs killer T-cells to target and destroy cancer cells that express HER2/neu, a protein associated with epithelial tumors in breast, ovarian, pancreatic, colon, bladder and prostate cancers. NeuVax is comprised of a HER2/neu-derived peptide called E75. E75 is a nine-amino acid sequence that is immunogenic (produces an immune response) and GM-CSF is a commercially available protein that acts to stimulate and activate components of the immune system such as macrophages and dendritic cells.

The Company also develops novel applications for NeuVax based on preclinical studies and phases 2 clinical trials which suggest that combining NeuVax and trastuzumab (Herceptin; Genentech/Roche) can increase antigen presentation by tumor cells by promoting receptor internalization and subsequent proteosomal degradation of the HER2 protein. The Company also is pursuing additional therapeutic indications for NeuVax that are in Phase 1/2 clinical trials. RXI-109, is a dermal anti-scarring therapy that ! targ! ets! conne! ctive tissue growth factor (CTGF) and that may inhibit connective tissue formation in human fibrotic disease.

The Company competes with Roche Laboratories, Inc., Pfizer Inc., Bayer HealthCare AG, Sanofi-Aventis, US, LLC, Amgen, Inc., GlaxoSmithKline plc, Renovo Group plc, CoDa Therapeutics, Inc., Sirnaomics, Inc., FirstString Research, Inc., Merz Pharmaceuticals, LLC, Capstone Therapeutics, Halscion, Inc., Garnet Bio Therapeutics, Inc., AkPharma Inc., Promedior, Inc., Kissei Pharmaceutical Co., Ltd., Eyegene, Derma Sciences, Inc., Healthpoint Biotherapeutics, Pharmaxon, Excaliard Pharmaceuticals, Inc., Alnylam Pharmaceuticals, Inc., Marina Biotech, Inc., Tacere Therapeutics, Inc., Benitec Limited, OPKO Health, Inc., Silence Therapeutics plc, Quark Pharmaceuticals, Inc., Rosetta Genomics Ltd., Lorus Therapeutics, Inc., Tekmira Pharmaceuticals Corporation, Arrowhead Research Corporation, Regulus Therapeutics Inc. and Santaris.

Hot Biotech Stocks To Watch Right Now: Applied Nanotech Holdings Inc (APNT)

Applied Nanotech Holdings, Inc., incorporated on May 22, 1989, is engaged in nanotechnology research and development business. The Company's nanotechnology research involves performing contract research and development services for others to develop products and materials for new applications, and then leveraging this research by applying it to other similar applications in other industries. The Company also develops intellectual property (IP) around its products and technologies. The Company develops five technology platforms: nanosensor technology; nanocomposites, based on carbon nanotube composites; thermal management materials; nanoelectronics applications, and electron emission activities, primarily in the display area. The Company's electron emission IP is divided into display activities and non-display activities. Applied Nanotech Holdings, Inc. is the parent company. Applied Nanotech, Inc. (ANI) is a subsidiary of ANHI. During the year ended December 31, 2012, the Company formed EZDiagnostix, Inc., (EZDX).

Sensors

The Company develops sensors based on ion mobility sensor technology and differential mobility spectroscopy. The Company is involved in projects to develop Mercaptan and Methane sensors for uses in the natural gas industry. The Company is also applying this technology to other applications, including agricultural pathology, wound care, and breath analysis. The Company develops hydrogen sensor for use in the measurement of hydrogen in power transformer products. The Company develops carbon monoxide sensor that can last for 10,000 hours on a single battery. The Company's carbon nanotube technology is for use in biosensors. Sensors based on carbon nanotubes or other nanomaterials can be used to detect chemical, organic, or biological warfare agents, as well as explosives, hydrogen, ammonia and numerous other chemicals.

Nanocomposites

The Company is in the advanced stages of development of nanomaterials using carbon nanotube (CNT) and! other composites. Epoxies are used in industries with worldwide markets, with applications, including adhesives, paints, coatings, and composites. In addition to epoxy resins, the Company develops other types of resins, including polyesters and vinyl esters. Vinyl esters are used in a variety of industrial applications, including storage tanks, piping, and construction. The Company develops a process for coating nylon pellets with CNTs to improves electrical conductivity. Nylon 6 with improved electrical conductivity can be used for its anti-static qualities, electrostatic discharge, and electromagnetic/RF shielding.

Thermal Management

The Company markets thermal management material called CarbAl. CarbAl provides a passive thermal management solution for temperature control issues that plague electronics manufacturers. CarbAl is a carbon based metal nanocomposite comprised of 80% carbonaceous matrix and a dispersed metal component of 20% aluminum. The Company also develops a simplified version of CarbAl based on graphite.

Conductive Inks

The Company develops aluminum and silver inks and pastes that is ideal for use in the production of solar cells. The Company also develops aluminum paste that can be used in current solar cell production.

The Company competes with Zyvex Performance Materials, GSI Creos, Amroy Europe, Ltd., DuPont and Ferro

Hot Biotech Companies To Invest In Right Now: NeoStem Inc (NBS)

NeoStem, Inc., incorporated on September 18, 1980, operates in cellular therapy industry. Cellular therapy addresses the process by which new cells are introduced into a tissue to prevent or treat disease, or regenerate damaged or aged tissue, and consists of a separate therapeutic technology platform in addition to pharmaceuticals, biologics and medical devices. The Company�� business model includes the development of novel cell therapy products, as well as operating a contract development and manufacturing organization (CDMO) providing services to others in the regenerative medicine industry. Progenitor Cell Therapy, LLC, the Company�� wholly owned subsidiary (PCT), is a CDMO in the cellular therapy industry. PCT has provided pre-clinical and clinical current Good Manufacturing Practice (cGMP) development and manufacturing services to over 100 clients advancing regenerative medicine product candidates through rigorous quality standards all the way through to human testing.

PCT has two cGMP, cell therapy research, development, and manufacturing facilities in New Jersey and California, serving the cell therapy community with integrated and regulatory compliant distribution capabilities. Its core competencies in the cellular therapy industry include manufacturing of cell therapy-based products, product and process development, cell and tissue processing, regulatory support, storage, distribution and delivery and consulting services. The Company�� wholly-owned subsidiary, Amorcyte, LLC (Amorcyte) is developing its own cell therapy, AMR-001, for the treatment of cardiovascular disease. AMR-001 represents its clinically advanced therapeutic product candidate and enrollment for its Phase II PreSERVE clinical trial to investigate AMR-001's safety and efficacy in preserving heart function after a heart attack in a particular type of post Acute Myocardial Infarction (AMI) patients.

Through the Company�� subsidiary, Athelos Corporation (Athelos), the Company is collaborating w! ith Becton-Dickinson in early stage clinical development of a therapy utilizing T-cells, collaborating for autoimmune and inflammatory conditions, including but not limited to, graft vs. host disease, type 1 diabetes, steroid resistant asthma, lupus, multiple sclerosis and solid organ transplant rejection. The Company�� pre-clinical assets include its Very Small Embryonic Like (VSEL) Technology platform. The Company has basic research and development capabilities, manufacturing facilities on both the east and west coast of the United States.

Hot Biotech Stocks To Watch Right Now: Incyte Corporation(INCY)

Incyte Corporation focuses on the discovery and development of proprietary small molecule drugs for hematologic and oncology indications, and inflammatory and autoimmune diseases. Its product pipe line includes INCB18424, which is in Phase III clinical trial for myelofibrosis; Phase III trial for polycythemia vera; Phase III trial for essential thrombocythemia; Phase I/II trial to treat solid tumors/other hematologic malignancies; and Phase IIb trail for the treatment of psoriasis. The company?s portfolio also includes INCB28050, a Phase IIb clinical trial product for rheumatoid arthritis; INCB28060, a Phase I/II product for solid tumors; INCB7839, a Phase II product for breast cancer; and INCB24360, a Phase I/II product for solid tumors. It has a collaborative research and license agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; and Pfizer Inc. The company was founded in 1991 and is headquartered in Wilmington, Delaware.

Hot Biotech Stocks To Watch Right Now: Cell Therapeutics Inc (CTIC.A)

Cell Therapeutics, Inc. (CTI), incorporated in 1991, develops, acquires and commercializes treatments for cancer. The Company�� research, development, acquisition and in-licensing activities concentrate on identifying and developing new ways to treat cancer. As of December 31, 2011, CTI focused its efforts on Pixuvri (pixantrone dimaleate) (Pixuvri), OPAXIO (paclitaxel poliglumex) (OPAXIO), tosedostat, brostallicin and bisplatinates. As of December 31, 2011, it developed Pixuvri, an anthracycline derivative for the treatment of hematologic malignancies and solid tumors. Another late-stage drug candidate of the Company, OPAXIO, is being studied as a potential maintenance therapy for women with advanced stage ovarian cancer, who achieve a complete remission following first-line therapy with paclitaxel and carboplatin. As of December 31, 2011, it also developed tosedostat in collaboration with Chroma Therapeutics, Ltd. (Chroma). On May 31, 2012, CTI completed its acquisi tion gaining worldwide rights to S*BIO Pte Ltd.'s (S*BIO) pacritinib.

Pixuvri

As of December 31, 2011, the Company developed Pixuvri, an aza-anthracenedione derivative, for the treatment of non-Hodgkin�� lymphoma (NHL), and various other hematologic malignancies, and solid tumors. Pixuvri was studied in the Company�� EXTEND, or PIX301, clinical trial, which was a phase III single-agent trial of Pixuvri for patients with relapsed, refractory aggressive NHL who received two or more prior therapies and who were sensitive to treatment with anthracyclines. On September 28, 2011, CTI announced that a second independent radiology assessment of response and progression endpoint data from its PIX301 clinical trial of Pixuvri was achieved with statistical significance. The results of the EXTEND trial met its primary endpoint and showed that patients randomized to treatment with Pixuvri achieved a significantly higher rate of confirmed and unconfirmed co mplete response compared to patients treated with standard! c! hemotherapy had a significantly increased overall response rate and experienced a statistically significant improvement in median progression free survival. Pixuvri had predictable and manageable toxicities when administered at the proposed dose and schedule in the EXTEND clinical trial in heavily pre-treated patients. In March 2011, the Company initiated the PIX-R trial to study Pixuvri in combination with rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Pixuvri has also been studied in patients with HER2-negative metastatic breast cancer who have tumor progression after at least two, but not more than three, prior chemotherapy regimens. In the second quarter of 2010, the NCCTG opened this phase II study for enrollment. The study is closed to accrual and results are expected to be reported by the NCCTG later in 2012.

OPAXIO

OPAXIO is the Company�� biologically-enhanced chemotherapeutic agent that links pacli taxel to a biodegradable polyglutamate polymer, resulting in a new chemical entity. As of December 31, 2011, the Company focused its development of OPAXIO on ovarian, brain, esophageal, head and neck cancer. OPAXIO was designed to improve the delivery of paclitaxel to tumor tissue while protecting normal tissue from toxic side effects. In November 2010, results were presented by the Brown University Oncology Group from a phase II trial of OPAXIO combined with temozolomide (TMZ), and radiotherapy in patients with newly-diagnosed, high-grade gliomas, a type of brain cancer. The trial demonstrated a high rate of complete and partial responses and a high rate of six month progression free survival (PFS). Based on these results, the Brown University Oncology Group has initiated a randomized, multicenter, phase II study of OPAXIO and standard radiotherapy versus TMZ and radiotherapy for newly diagnosed patients with glioblastoma with an active gene termed MGMT that reduces respons iveness to TMZ. A phase I/II study of OPAXIO combined ! with r! a! diothera! py and cisplatin was initiated by SUNY Upstate Medical University, in patients with locally advanced head and neck cancer.

Tosedostat

In March 2011, the Company entered into a co-development and license agreement with Chroma Therapeutics, Ltd. (Chroma), providing the Company with marketing and co-development rights to Chroma�� drug candidate, tosedostat, in North, Central and South America. Tosedostat is an oral, aminopeptidase inhibitor that has demonstrated anti-tumor responses in blood related cancers and solid tumors in phase I-II clinical trials. Interim results from the phase II OPAL study of tosedostat in elderly patients with relapsed or refractory acute myeloid leukemia (AML) showed that once-daily, oral doses of tosedostat had predictable and manageable toxicities and results demonstrated response rates, including a high-response rate among patients who received prior hypomethylating agents, which are used to treat myelodysplastic synd rome (MDS), a precursor of AML.

Brostallicin

As of December 31, 2011, the Company developed brostallicin through its wholly owned subsidiary, Systems Medicine LLC, which holds rights to use, develop, import and export brostallicin. Brostallicin is a synthetic deoxyribonucleic acid (DNA) minor groove binding agent that has demonstrated anti-tumor activity and a favorable safety profile in clinical trials, in which more than 230 patients have been treated as of December 31, 2011. The Company uses a genomic-based platform to guide the development of brostallicin. A phase II study of brostallicin in relapsed, refractory soft tissue sarcoma met its predefined activity and safety hurdles and resulted in a first-line phase II clinical trial study that was conducted by the European Organization for Research and Treatment of Cancer (EORTC).

The Company competes with Bristol-Myers Squibb Company, Sanofi-Aventis, Pfizer, Roche Group, Genentech, Inc., Astellas Pharma, Eli Lilly and Company, Cel! gene, Tel! ik! , Inc., T! EVA Pharmaceuticals Industries Ltd. and PharmaMar.